Examining the Evidence in Frontline Therapy
|Managing Myeloma: Examining the Evidence in Frontline Therapy |
CME, CPE, CNE
Amrita Krishnan, MD, FACP and Saad Z. Usmani, MD, MBA, FACP
|Release Date: January 30, 2023|
Expiration Date: January 30, 2024
In recent years, important new advances have been reported in the frontline treatment of newly diagnosed multiple myeloma (NDMM) patients. Despite this progress, however, significant challenges remain. In this activity, two myeloma experts will discuss the most recent information and evidence regarding frontline therapy including selecting regimens based on individual patient disease factors, treatment regimens for transplant-ineligible and transplant-eligible patients, and key practice considerations for NDMM.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol Myers Squibb Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
|Begin, Earn CreditView Only, No Credit|